A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia

This publication has 40 references indexed in Scilit:

• Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
  Cancer, 2005
• Results of triple therapy with interferon‐alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in early chronic phase
  Cancer, 2003
• Homoharringtonine
  Cancer, 2001
• Acute myeloid leukaemia (AML): treatment of the older patient
  Best Practice & Research Clinical Haematology, 2001
• Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation
  FEBS Letters, 1989
• Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-β-D-arabinofuranosylcytosine
  Cancer Chemotherapy and Pharmacology, 1989
• Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor α on Colon 38 tumours in mice
  European Journal of Cancer and Clinical Oncology, 1989
• Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure?
  JNCI Journal of the National Cancer Institute, 1988
• Homoharringtonine: a phase I evaluation
  Investigational New Drugs, 1985
• Inhibition of Translation in Eukaryotic Systems by Harringtonine
  European Journal of Biochemistry, 1977